Pfizer's Emini targets pneumonia market with Prevnar 13; Online vaccines available from suspect sources;

> In November, Pfizer ($PFE) won expert backing for the use of its vaccine Prevnar 13 to protect adults over 50 from pneumococcal infections. If the FDA agrees with the panel's decision--and it usually does--Pfizer could have an expanded approval of the blockbuster vaccine in hand by January. And heading up Pfizer's vaccine efforts is Emilio Emini, who came to the company in Pfizer's buyout of Wyeth in 2009. Report

> Researchers from the University of Arizona have developed a vaccine grown in tobacco plants that protected 80% of mice from contracting Ebola, a hemorrhagic fever that kills 90% of the people it infects. Article

> Inovio Pharmaceuticals, which has a pipeline of synthetic vaccines for cervical cancer, HIV and malaria, announced that it's raised $4 million in a public offering. The money will be used to support clinical work and R&D activities. Report

> The PATH Malaria Vaccine Initiative, the National Institute of Allergy and Infectious Diseases and the Johns Hopkins Bloomberg School of Public Health Center for Immunization Research are teaming up to conduct a Phase I trial of a new malaria vaccine called Pfs25. Report

And Finally... Looking for a vaccine that's in short supply? Don't be fooled by internet vendors. More than 83% of the online vendors of vaccines have made the "Not Recommended Site" list of the National Association of Boards of Pharmacy. Report

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.